Patient preferences, anticoagulant benefit versus risk and limited life expectancy should be considered when managing anticoagulation treatment at the end of a patient’s life.
“We have a lot of guidelines that cover when to start anticoagulants, but they’re conspicuously lacking for when and how to stop them,” said Anna Parks, MD, an assistant professor and the director of thrombosis at the University of Utah, in Salt Lake City. Decisions can be challenging